Liraglutide 3 mg Investigated for Weight Loss and Appetite Regulation in Obese Type 2 Diabetics

The global prevalence of obesity and Type 2 Diabetes (T2D) continues to rise, often co-existing and exacerbating each other. Current treatments for T2D, such as sulfonylureas, can sometimes lead to weight gain, complicating obesity management. There's a critical need for therapies that effectively manage glycemic control while also promoting weight loss. Glucagon-like peptide-1 (GLP-1) receptor agonists, like liraglutide, offer a promising avenue by enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite, addressing both metabolic and weight-related challenges.

This European clinical trial investigated liraglutide 3.0 mg in obese subjects with Type 2 Diabetes already on diet and/or sulphonylurea or repaglinide. Participants underwent a 12-week run-in period involving a low-calorie diet. Those who achieved at least 5% body weight loss during the run-in were randomized to receive liraglutide 3.0 mg, administered once daily via subcutaneous injection. The study aimed to evaluate the effect of this regimen on weight and appetite, though specific details on the comparator arm or the full duration of the intervention phase were not provided in the abstract.

Specific numerical findings, statistical data, or detailed results regarding weight loss, appetite changes, or other primary endpoints were not provided in the abstract. Therefore, no concrete data points, percentages, p-values, or fold-changes can be reported from the provided text. The abstract primarily outlines the study's objective and design rather than its outcomes. Further details would be required to ascertain the efficacy or safety profile observed in this particular investigation.